(CercleFinance.com) – AstraZeneca announced that results from a phase III trial showed that Tagrisso (osimertinib) combined with chemotherapy demonstrated a 42% improvement in central nervous system progression-free survival (PFS) ( CNS), compared to Tagrisso alone in patients with locally advanced or metastatic epidermal growth factor receptor (EGFRm)-mutated non-small cell lung cancer (NSCLC) and brain metastases at baseline.
In this group of patients, the Tagrisso + chemotherapy protocol reduced the risk of CNS disease progression or death by 42% compared to Tagrisso alone.
After two years of follow-up, 74% of patients treated with Tagrisso + chemotherapy did not experience CNS disease progression or death, compared to 54% of patients treated with Tagrisso monotherapy.
“In this trial, the addition of chemotherapy to osimertinib led to a complete response and the disappearance of these brain tumors, in more than half of these patients,” commented David Planchard, thoracic oncologist at the Gustave Roussy Institute of Oncology and principal investigator of the trial.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
